BBIO in the 13F filings
Bridgebio Pharma Inc · CUSIP 10806X102
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 35
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 17 listed it in both
- Shares listed
- 73,047,480
- combined, among listed positions
- Reported value
- $5.4bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 24 buyers (opened or added shares) and 15 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +7,455,155.
Managers listing BBIO in Q2 2026
35 of 35 holders
Largest increases and reductions, by shares
Increases
- Wellington Management Group LLPexisting position · 5,308,924 shares now+2,824,971
- Two Sigma Investments LPexisting position · 4,722,185 shares now+1,601,554
- Point72 Asset Management LPnew position · 1,525,782 shares now+1,525,782
- Farallon Capital Management LLCexisting position · 10,743,063 shares now+1,377,600
- Jane Street Group LLCexisting position · 2,934,193 shares now+1,176,521
Reductions
- T. Rowe Price Associates Incexisting position · 1,726,383 shares now-2,075,272
- Viking Global Investors LPexisting position · 9,949,219 shares now-1,893,215
- Invesco Ltdexisting position · 3,700,934 shares now-891,880
- AllianceBernstein LPexisting position · 1,453,504 shares now-455,403
- Fidelity (FMR LLC)existing position · 2,061,307 shares now-282,447
New positions and exits
New (7)
Exited (4)
- Voloridge Investment Management LLCwas $32m
- Artisan Partners LPwas $19m
- Winton Group Ltdwas $3.6m
- MFS Investment Managementwas $240k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 2 | $719m | n.a. | n.a. |
| Q3 2019 | 1 | $572m | n.a. | n.a. |
| Q4 2019 | 2 | $1.0bn | n.a. | n.a. |
| Q1 2020 | 3 | $824m | n.a. | n.a. |
| Q2 2020 | 4 | $926m | n.a. | n.a. |
| Q3 2020 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.0bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 5 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 4 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 2 | $452m | n.a. | n.a. |
| Q1 2022 | 2 | $276m | n.a. | n.a. |
| Q2 2022 | 2 | $246m | n.a. | n.a. |
| Q3 2022 | 3 | $271m | n.a. | n.a. |
| Q4 2022 | 2 | $204m | n.a. | n.a. |
| Q1 2023 | 4 | $477m | n.a. | n.a. |
| Q2 2023 | 2 | $463m | n.a. | n.a. |
| Q3 2023 | 9 | $898m | n.a. | n.a. |
| Q4 2023 | 9 | $1.3bn | 1 | 7 |
| Q1 2024 | 7 | $1.1bn | 5 | 2 |
| Q2 2024 | 4 | $826m | 2 | 0 |
| Q3 2024 | 8 | $927m | 7 | 0 |
| Q4 2024 | 7 | $1.2bn | 4 | 3 |
| Q1 2025 | 9 | $1.6bn | 6 | 3 |
| Q2 2025 | 15 | $2.3bn | 11 | 4 |
| Q3 2025 | 14 | $2.3bn | 5 | 9 |
| Q4 2025 | 18 | $4.3bn | 22 | 12 |
| Q1 2026 | 20 | $4.4bn | 20 | 14 |
| Q2 2026 | 18 | $4.5bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BBIO and LLY →BBIO and JNJ →BBIO and VRTX →Choose a stock to compare with BBIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BBIO, latest filings →Back to the 13F Explorer →